What question did this study set out to answer?

The aim is to assess the effectiveness and safety of upadacitinib in patients with difficult-to-treat Crohn's disease.

January 23, 2026Journal of Crohn s and Colitis

P0786Real-world effectiveness and safety of upadacitinib in difficult-to-treat Crohn’s Disease: A national multicenter study from China

View Full Paper

Ask AI

Bookmark

The aim is to assess the effectiveness and safety of upadacitinib in patients with difficult-to-treat Crohn's disease.
Conducted an ambidirectional, national, multicenter study in eight Chinese IBD centers.
Included patients meeting IOIBD criteria for difficult-to-treat Crohn’s disease.
Administered upadacitinib 45 mg daily for 12 weeks, followed by 15 mg daily for maintenance.
Evaluated efficacy at weeks 12 and 24, with primary endpoint at week 24.
Recorded adverse events at both assessment points.
Clinical remission rate at week 24 was 63.2%.
Endoscopic remission rate at week 24 was 28.9%.
At week 24, 82.9% achieved clinical response; 42.2% achieved endoscopic response.
Reported 42 adverse events by week 12, with no serious adverse events observed.
Nine patients discontinued treatment by week 24, primarily due to serious adverse events.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

A national multicenter study evaluates upadacitinib's efficacy and safety in Crohn's disease, indicating its potential as a valuable treatment option.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69730fc4c8125b09b0d1f88a https://doi.org/10.1093/ecco-jcc/jjaf231.967

View Full Paper

Ask AI

Bookmark

Implication

A national multicenter study evaluates upadacitinib's efficacy and safety in Crohn's disease, indicating its potential as a valuable treatment option.

P0786Real-world effectiveness and safety of upadacitinib in difficult-to-treat Crohn’s Disease: A national multicenter study from China

Key Points

Discussion

Implication

Cite This Study

P0786Real-world effectiveness and safety of upadacitinib in difficult-to-treat Crohn’s Disease: A national multicenter study from China

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading